Holen Sie sich die Stockscreener-App
32.30
4.72%
1.44
Tyra Biosciences Inc Aktie (TYRA) Neueste Nachrichten
Enterprise value to EBITDA forward of Tyra Biosciences, Inc. – NASDAQ:TYRA - TradingView
Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data? - Insider Monkey
Bladder Cancer Pipeline Expands as 80+ Companies Driving Innovation in the Therapeutics | DelveInsight - Barchart.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2500 Growth Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Growth Benchmark - marketscreener.com
(TYRA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Tyra Biosciences, Inc.(NasdaqGS:TYRA) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell Microcap Index - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell 3000 Value Benchmark - marketscreener.com
Tyra Biosciences, Inc.(NasdaqGS: TYRA) dropped from Russell 2500 Value Benchmark - marketscreener.com
10 Most Promising Cancer Stocks According to Wall Street Analysts - Insider Monkey
Tyra Biosciences, Inc.(NasdaqGS:TYRA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Form 144 TYRA BIOSCIENCES For: 26 June By Investing.com - Investing.com Nigeria
Form 144 | TYRA BIOSCIENCES, INC.(TYRA.US) Insider Proposes to Sell 9.54 Million in Common Stocks - Moomoo
TYRA (NASDAQ: TYRA) sells common shares under Rule 144 in June 2026 - Stock Titan
Tyra Bioscience, Inc Actuals & Estimates (NASDAQ:TYRA) - TradingView
Tyra Biosciences (TYRA) Gains Attention On Phase II Results, Is The Upside Already Priced In? - Sahm
TYRA Forecast — Price Target — Prediction for 2027 - TradingView
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
JonesTrading Initiates TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Announces Target Price $56 - 富途牛牛
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42 - 富途牛牛
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight - Yahoo Finance
Tyra Biosciences Inc (TYRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Tyra Biosciences (TYRA) Slips 2.58%: Support Level in Focus After Weekly DeclineReversal Trade - dars.gov.et
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Analysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), Tyra Bioscience (TYRA) - The Globe and Mail
Tyra Biosciences Inc (TYRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Tyra Biosciences Inc (TYRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Tyra Biosciences Inc (TYRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Tyra Biosciences Inc (TYRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Tyra Biosciences Inc (TYRA) Institutional Confidence - TradingKey
Tyra Biosciences Inc (TYRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Tyra Biosciences Inc (TYRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Tyra Biosciences Inc (TYRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
TYRA PE Ratio & Valuation, Is TYRA Overvalued - Intellectia AI
TYRA Initiated Coverage by Jones Trading -- Rating Set to Buy - GuruFocus
Wedbush Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $53 - Moomoo
TYRA Q1 2026 Earnings: EPS Miss Amid Pre-Revenue Stage, Stock Gains 5.55%Earnings Seasonality - newsline.com
Tyra Biosciences (TYRA) Surges 5.55% on Strong Volume, Testing Key Resistance LevelsCash Flow Strong Stocks - newsline.com
Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism? - Yahoo Finance
Urothelial Carcinoma Market on Track for Major Expansion - openPR.com
Urothelial Carcinoma Market on Track for Major Expansion by 2036, According to DelveInsight | Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Infinity - Barchart.com
Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says - Moomoo
TYRA Maintains Rating by B of A Securities -- Price Target Raised to $42 - GuruFocus
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.8, Implies 96% Upside - TradingView
BofA Securities Raises Price Target on Devon Energy to $42 From $37, Buy Rating Kept - marketscreener.com
BofA raises Tyra Biosciences stock price target on safety outlook By Investing.com - Investing.com Nigeria
Analyst Initiates Buy on Tyra Biosciences, Citing De-Risked Dabogratinib Program and Attractive Entry Ahead of Key Bladder Cancer Data - TipRanks
BofA raises Tyra Biosciences stock price target on safety outlook - Investing.com
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - 富途牛牛
TYRA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Tyra Biosciences (TYRA) Declines 1.67% as Stock Tests Key Support LevelsCovered Call Trade - newsline.com
Raymond James reiterates Strong Buy on Tyra Biosciences stock amid recent weakness - Investing.com Canada
1.88%
2.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):